SCHEMBL3059779

SCHEMBL3059779

N#Cc1ccccc1N(Cc1ccccc1)C(=O)c1ccncc1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.52
MEN1 O00255 3/20 0.52
NPC1 O15118 1/20 0.52
TSHR P16473 2/20 0.48
GAA P10253 1/20 0.46
TDP1 Q9NUW8 1/20 0.44
LPAR1 Q92633 1/20 0.44
LPAR5 Q9H1C0 1/20 0.44
MLYCD O95822 1/20 0.42
KDM4E B2RXH2 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
TRPM8 Q7Z2W7 1/20 0.40
MAPK14 Q16539 1/20 0.40
TAS2R14 Q9NYV8 1/20 0.40
ACHE P22303 1/20 0.39
LMNA P02545 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
OXTR P30559 1/20 0.39
AVPR1A P37288 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3054184 0.83 TRPM8 (0.45) KMT2AMEN1NPC1TSHRGAA
SCHEMBL3064804 0.80 TRPM8 (0.63) KMT2AMEN1NPC1TSHRGAA
SCHEMBL3058316 0.78 TSHR (0.49) KMT2AMEN1NPC1TSHRGAA
SCHEMBL3060251 0.78 TSHR (0.71) KMT2AMEN1NPC1TSHRGAA
SCHEMBL3053508 0.77 TSHR (0.48) KMT2AMEN1NPC1TSHRGAA
SCHEMBL3054619 0.77 TRPM8 (0.52) KMT2AMEN1NPC1TSHRGAA
SCHEMBL9575668 0.75 MEN1 (0.43) KMT2AMEN1NPC1TDP1LPAR1
SCHEMBL3056500 0.75 TSHR (0.49) KMT2AMEN1NPC1TSHRGAA
SCHEMBL3044606 0.74 KMT2A (0.65) KMT2AMEN1NPC1TSHRGAA
SCHEMBL3067512 0.73 TSHR (0.47) KMT2ANPC1TSHRGAAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100261758-A1 HETEROCYCLIC AMIDES FOR USE AS PHARMACEUTICALS NOVARTIS AG (CH) 2010-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261758-A1 HETEROCYCLIC AMIDES FOR USE AS PHARMACEUTICALS HRH4, CNR1, CNR2 KMT2A 1989/4885MEN1 1499/4885NPC1 736/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.